Evidence map›Paper›PMID 31427509›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2019

A high-throughput system to identify inhibitors of

Melanie J Barnett, David E Solow-Cordero, Sharon R Long

Open access · bronzeAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
9.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 61 citations in OpenAlex.

  1. Article
  2. Article
  3. Frontiers in microbiology · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. 'Autophagy · 2023
    Article
  10. Article
  11. Evaluation ofMolecules (Basel, Switzerland) · 2022
    Article
  12. Article
  13. A serralysin-like protein ofFrontiers in microbiology · 2022
    Article
  14. An Overview of the Mechanisms Against "Frontiers in microbiology · 2022
    Review
  15. Review
  16. Structure of Lipopolysaccharide fromInternational journal of molecular sciences · 2021
    Article
  17. Article
  18. A promising plant defense peptide against citrus Huanglongbing disease.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  19. A stable antimicrobial peptide with dual functions of treating and preventing citrus Huanglongbing.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  20. Defeating Huanglongbing PathogenFrontiers in plant science · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Melanie J BarnettDepartment of Biology, Stanford University, Stanford, CA 94305.
David E Solow-CorderoHigh-Throughput Bioscience Center, Stanford University, Stanford, CA 94305.
Sharon R LongDepartment of Biology, Stanford University, Stanford, CA 94305; srl@stanford.edu.
Stanford University · USHigh Throughput Biology (United States) · US

Funding

Control of Symbiotic Gene Expression in Sinorhizobium melilotiR01GM093628 · NIGMS · STANFORD UNIVERSITY · PI LONG, SHARON R · 2010 to 2017
$7.0M
NIGMS NIH HHS R01 GM093628
6 · The paper itself

Abstract

Citrus greening disease, also known as huanglongbing (HLB), is the most devastating disease of

Indexed as

Anti-Bacterial AgentsBacterial ProteinsCitrusDrug Evaluation, PreclinicalPlant DiseasesRhizobiaceaeTrans-ActivatorsAnti-Bacterial AgentsBacterial ProteinsTrans-ActivatorscitrusHuanglongbing (HLB)LiberibacterSinorhizobiumtranscription regulation

Identifiers

PMID31427509
PMCPMC6731658
OpenAlexW2969920246

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.